Prostate cancer medicine hailed as a "milestone" breakthrough may not be available to every patient after a revision of the drug guidelines, according to the NHS.
Men in England who have already been treated with a new-generation cancer drug would not be eligible for Enzalutamide, according to the National Institute for Health and Care Excellence (Nice).
Nice, the public body which decides the cost-effectiveness of medicines for NHS patients, said the new drug should not be used by patients who had already taken abiraterone.
Enzalutamide blocks molecular signals driving prostate cancer and improved survival by 30% in men who had not undergone chemotherapy.
A further 80% of men with advanced cancer had the progression delayed, even if the tumour had failed to respond to other treatments.
More top news
Rain will continue to swirl around an area of low pressure over the UK bringing further prolonged spells of rain to some areas.
As a deadline looms for talks to salvage power sharing in Northern Ireland, Sinn Fein has warned it is "make your mind up time for the DUP".
Female tennis players should play five-set matches because limiting them to three sets is "degrading", academics have argued.